Objective      To study the effects of hemoperfusion (HP) on lipid profiles and  blood pressure in patients with metabolic syndrome and  investigate the underlying mechanisms .       Methods      Blood routine test

blood biochemical

indexes

urine routine test

renal function

liver function and 4 contagious indexes before blood transfusion were examined before HP. A total of 26 patients with metabolic syndrome were qualified for HP. All patients were followed-up

with blood pressure monitored. The levels of blood lipids

angiotensin Ⅰ (AⅠ)

angiotensin Ⅱ (AⅡ)

aldosterone (Ald)

hypersensitive C-reactive protein (hs-CRP)

monocyte chemotactic protein 1 (MCP-1) and resistin were measured at 4

8  and 12 weeks after HP. SPSS19 statistical software

including the single sample 

t

test

Pearson correlation analysis and other methods

was used to compare the results.       Results      The total cholesterol (TC) and triglyceride (TG) levels were significantly reduced after HP within 8 weeks as compared to the baseline values (

P

0.05). The systolic pressure (SBP) and  serum resistin levels were decreased significantly within 12 weeks as compared to those before the treatment (SBP: 143±15 

vs

137±17 mmHg

P

0.05; resistin: 2.06±2.02 

vs

0.65±0.42 ng/mL

P

0.05). The bivariate correlation analysis showed that the SBP was positively correlated with TC and resistin levels (

r

=0.40

P

=0.00;

r

=0.29

P

=0.003).       Conclusion      HP can effectively reduce blood lipid levels and lower blood pressure of patients with metabolic syndrome

which may be related to removal of serum resistin and blood lipids by HP.